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Abstract 
Plasma cells develop from B-lymphocytes following stimulation by antigen and express a 
genetic program aimed at the synthesis of immunoglobulins. This program includes the 
induction of genes coding for transcription factors such as PRDM1 and XBP1, cell-surface 
molecules such as CD138/syndecan-1 and for the unfolded protein response (UPR). We 
review how the microarray technology has recently contributed to the understanding of the 
biology of this rare but essential cell population and its transformation into pre-malignant and 








Plasma cells (PCs) – or antibody-secreting cells (ASC) – are the terminally 
differentiated B lymphocytes devoted to the task of synthesizing immunoglobulins (Ig). Most 
PCs are located in the bone marrow where they constitute a very small cell population (0.5 % 
of bone marrow cells) that may survive for months or even years (1). They are the major 
source of circulating Ig. Antibodies are the effectors of humoral specific immunity, 
conjugating remarkable specificity and high efficacy in destroying their targets. Because Ig 
are crucial for the protection of the organism against microorganisms but may be the cause of 
serious hazard in the form of autoimmunity, the differentiation, proliferation and survival of 
PCs are tightly regulated. The high specificity of the antibodies is the result of several DNA 
modifying events involving mutations in variable Ig gene mutations and Ig chain switch. 
Error in Ig switch process can lead to an illegitimate activation of oncogenes that are 
considered as the first step of a process that changes a B lymphocyte into an uncontrolled 
proliferating premalignant or malignant PC in the bone marrow of patients with monoclonal 
gammopathy with undetermined significance (MGUS) or with multiple myeloma (MM). We 
will review how microarrays have recently contributed to the understanding of the biology of 
this rare but essential cell population and its transformation into pre-malignant and malignant 
PCs. 
 
2. Normal plasma cells 
Using gene expression profiling (GEP) with Affymetrix microarrays on purified cell 
populations of plasmablasts and bone marrow mature PCs, we were recently able to build a 
molecular portrait of 125 genes involved in differentiation of B cells into plasmablasts and 
subsequently into bone marrow PCs (BMPCs) (2). We are currently extending these results by 
comparing the molecular profiling of 7 normal bone marrow BMPC samples and 7 
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plasmablasts samples, to that of 7 B memory lymphocytes samples using pan genomic 
microarrays. This genome wide screen shows that 2482 probes (5.4% of the 44 760 probes 
used) are differentially expressed between memory B cells and BMPC with a p-value ≤ 0.01 
(Kruskal-Wallis non parametric test) and a fold change of a least 3 (manuscript in 
preparation). These modifications include transcription factors, cell surface molecules and 
enzymes involved in metabolism, especially in protein processing. 
 
2.1. The plasma cell transcription factor network 
 Differentiation of a B lymphocyte into a PC is driven by a profound modification of 
the transcription factor network (Figure 1A). This has been comprehensively reviewed by K. 
Calame and collaborator (Shapiro-Shelef and Calame 2005). The transcriptional repressor 
PRDM1/PRDI-BF1/BLIMP1 is the master regulator of terminal B cell development and is 
sufficient to drive primary mouse splenocytes into antibody-secreting PCs (3). Lack of 
PRDM1 in B lymphocytes causes a profound defect in Ig synthesis due to a lack of PC 
formation (4). PRDM1 expression is increased over 4 times during PC differentiation, as early 
as in proliferating plasmablast stage (Figure 1B). Genes regulated by PRDM1 have been 
extensively studied by microarrays (5). Genes identified as directly repressed by PRDM1 due 
to binding sites to this transcription factor in their promoter include PAX5, SPIB/Spi-B, ID3, 
CTIIA and MYC (5, 6). PRDM1 expression also blocks immunoglobulin class switching by 
blocking the expression of AID, KU70, KU86, DNA-PKCs and STAT6 (5). One key regulator 
of PRDM1 expression was identified by a microarray screen, the six-zinc-finger-containing 
transcriptional repressor BCL6 (7). BCL6 is essential for the generation of germinal centers 
where it is highly expressed and prevents the expression of the TP53/p53 suppressor gene (8) 
and the expression of PRDM1 (7). Repression by BCL6 depends on MTA3 expression, a 
subunit of the corepressor complex MI-2/NuRD (9). Downregulation of paired box protein 5 
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(PAX5)/BSAP gene is one of the main consequence of the upregulation of PRDM1 and is 
necessary for the PC differentiation program to proceed (10). PAX5 is essential for B-lineage 
commitment and activates the expression of genes such as VpreB and CD19 and represses the 
expression of genes switched on in PCs such as heavy chain Ig (IgH) and XBP1. Other 
transcription factors that are characteristic of B lymphocytes are silenced upon plasma-cell 
differentiation, such as BACH1 and BACH2 (11), or EBF (12). The modifications of this 
transcription factor network are comprehensively captured by microarrays as shown in Figure 
1B. Other transcription factors important for PC formation include IRF4 and OBF1 – the later 
only for T-cell dependant PCs (13, 14). Our results show that IRF4 is highly expressed at the 
plasmablast stage whereas OBF1 only show a modest increase during PC differentiation. 
 Most interestingly, the microarrays also uncover new transcription factors whose 
expression is strongly induced during PC differentiation. One of these transcription factors is 
BHLHB3/DEC2/SHARP1 (unpublished results), a class B basic helix-loop-helix transcription 
factor involved in the regulation of the molecular clock of the body (15). This transcription 
factor displays a remarkable high expression in normal PCs (Figure 1B) that is also observed 
in MM cells (data not shown). This pattern of expression strongly suggests that BHLHB3 may 
play a functional role during late B cell differentiation. 
 
2.2. The plasma cell phenotype 
Based on studies of reactive plasmacytosis and in vitro culture systems, at least three different 
PC stages can be identified by cell surface phenotyping during the differentiation process that 
transforms a germinal center B lymphocyte with a high affinity Ig to a mature PC residing in 
the bone marrow. The plasmablast is a CD20- CD38++ CD45++ CD126++ CD138- cell located 
in secondary lymphoid organs and transiently in the blood stream, and can be obtained from 
resting B memory cells in vitro (16-18). In the bone marrow, two populations differing in 
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their respective CD45 expression are found, early PCs that are CD20- CD38++ CD45++ 
CD126++ CD138++ whereas mature PCs are CD20- CD38++ CD45weak CD126+ CD138++. As 
illustrated by microarrays experiments (Figure 2), PC differentiation is characterized by the 
loss of pan-B markers (CD20, CD22, CD24), the up-regulation of CD38 starting from the 
plasmablast stage and the appearance of syndecan 1/CD138 late during development. In 
agreement with the role of IL-6 during PC differentiation, plasmablasts and/or mature PCs 
express 5 times more IL-6R/CD126 and GP130/CD130 than memory B cells (Figure 2). 
Down-regulation of CD45 expression characterizes the terminally differentiated, non 
proliferating mature PC stage. This characteristic is shared by primary myeloma cells (19). 
Conversely, a high expression of CD45 is observed on plasmablasts and early PCs as well as 
the proliferating fraction of the U266 human myeloma cell line (HMCL) (17, 20). Other 
surface markers vary during PC differentiation, including CD31 and CD54, which are found 
on mature PCs (16), CD39 which is specifically found on plasmablasts (Figure 2, unpublished 
results) and VCAM1. Some of these cell surface molecules (CD20, CD38, CD138) have been 
used to highly purify plasmablasts, tonsil or bone marrow PC by flow cytometry or using 
magnetic beads, and thus allowing a more specific molecular analysis using microarrays (2, 
16, 21, 22). 
 
2.3. The plasma cell homing 
 PC differentiation is a dynamic process during which a B lymphocyte expressing a 
high affinity Ig will leave the germinal center of secondary lymphoid organs to migrate, via 
the blood, to the bone marrow which is the principal site of long-lived ASC. The mature PC 
depends on survival signals provided by the microenvironment niche of the bone marrow. 
These “survival niches”, in which long lived PCs reside, appear to be limited in number. 
There is presumably competition among PC for these niches. Evidence for this hypothesis is 
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given by the fact that long lived PC without tetanus toxoid specificity are expulsed in the 
blood circulation after vaccination with tetanus toxin (23). The movement of the PC is under 
the control of repellent and attractant signals, involving chemokines, chemokine receptors, 
and adhesion molecules (24). 
2.3.1. Chemokines 
The chemokine receptor CXCR4 is a major determinant of the medullar localization of 
immature B lymphocytes and ASC. B-cell lineage and granulocytic precursors are released 
into the periphery in CXCR4-/- mice (25). In addition, reconstitution of hematopoiesis in 
irradiated mice with CXCR4-/- fetal liver cells results in the aberrant shift of PCs from the 
bone marrow to the blood circulation (26). Accordingly, CXCR4 expression is downregulated 
in plasmablasts which transit through the blood flow, before regaining a strong expression in 
BMPC (Figure 3). The mobilization of ASC is also linked to the loss of expression of two 
chemokine receptors, CCR7, a receptor for CCL19/ELC and CCL21/SLC, and CXCR5, a 
receptor for CXCL13/BLC (26). Both chemokine receptors are involved in the localization of 
B lymphocytes in secondary lymphoid organs, i.e. in the T-cell zone and the germinal centers, 
respectively (27). Loss of CCR7 and CXCR5 will increase the differentiating ASCs to respond 
to CXCL12/SDF1, the ligand of CXCR4, that is highly expressed by bone marrow stromal 
cells. 
 We previously observed, using cDNA macroarrays, that malignant PCs overexpress 
the chemokine receptors CCR1 and CCR2 as compared to lymphoblastoid cell lines (28). 
Microarray analysis of primary plasma cell samples has shown that CCR1 and CCR2 are 
overexpressed in both normal and malignant PC compared to B memory lymphocytes, CCR2 
is expressed starting at the plasmablast stage whereas CCR1 is only overexpressed in mature 
PC stage (Figure 3) (2, 16). The expression of MIP1alpha, one of the ligands of CCR1, is 
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induced during PC differentiation (see below, Figure 5). The preferential expression of these 
chemokine receptors is likely governing the homing of BMPCs to their bone marrow niche. 
2.3.2. Selectins and adhesion molecules 
 Plasmablasts transit from secondary lymphoid organs to the bone marrow. The 
mechanisms by which ASCs traffic are still unsatisfactorily understood, but adhesion and 
activation events regulating the migration of all subsets of circulating leukocytes are likely to 
apply to ASCs too (24). Circulating leukocytes tether to and roll on the endothelium through 
transient selectin–carbohydrate ligand interactions and/or integrin–CAM (cell cell-adhesion 
molecule) interactions. Rolling allow the cell to become sufficiently activated by locally 
released or displayed cytokines and chemoattractants to allow an integrin-mediated firm 
adhesion followed by diapedesis. By providing a large scale gene expression analysis of 
plasmablasts, microarrays have identified SELPLG/CD162/Selectin-P ligand as being 
strikingly upregulated during in vitro plasmablast generation (Figure 4) (16). In turn, the 
selectin-L/SELL/CD62L is lost between the stages of plasmablast and BMPC.  
Regarding integrins, figure 4 shows that two alpha chains are preferentially expressed in 
ASCs (2, 16). ITGA6 expression is switched on in plasmablasts and still increases when 
reaching the stage of BMPC as shown previously (29). ITGA8 is only expressed in BMPC. 
Because the integrin beta chain ITGB1 is expressed by PCs (Figure 4), the corresponding 
functional integrin heterodimers (α6β1 (VLA-6) and α8β1 (VLA-8)) are likely expressed on 
these cells. Conversely, the integrin alpha M/ITGAM/CD11b is strikingly downregulated 
early during PC differentiation. A very similar expression pattern of integrin alpha chains is 
found on malignant PCs (data not shown).  
 Other adhesion molecules upregulated during PC differentiation include vascular cell 
adhesion molecule 1 (VCAM1), intercellular adhesion molecule 2 (ICAM2) and the 
tetraspanin CD9 (Figure 4) (2). 
H
AL author m




2.4. Integrating extracellular cues 
 Interleukin-6 (IL-6) plays an important role in the normal PC physiology. Mice 
lacking this gene are impaired in T-cell-dependent antibody response (30), and conversely, 
transgenic mice expressing IL-6 under the control of the Eµ enhancer promoter trigger a fatal 
polyclonal plasmacytosis (31). In agreement with these findings in mice, IL-6 is a growth 
factor for nonmalignant human plasmablasts (32). As highlighted above, both chains of the 
IL-6 receptor are upregulated during PC differentiation (Figure 2), enabling the PC to respond 
to IL-6.  
Most long survival PCs home to the bone marrow. A privileged relationship between PCs, 
bone and the cells that mediate bone homeostasis, i.e. osteoblasts and osteoclasts, is very 
likely, but still very poorly characterized. By contrast, it is well documented that during the 
development of multiple myeloma, malignant PCs activate a large number of cell-to-cell 
signals that lead to the blockade of osteoblast activity and the concomitant stimulation of 
osteoclast activity (33). Whether this program is specific to the transformed PC or, at least in 
part, the execution of a physiological program that allows the nonmalignant PC to carve a 
survival niche in the bone marrow is an issue that awaits to be carefully addressed. It is 
therefore interesting to observe that microarray analysis of PCs identifies the secreted WNT 
antagonist FRZB/sFRP3 as a gene induced in BMPC (Figure 5) (28). Indeed, the WNT 
signaling pathway is important for the growth and differentiation of osteoblasts. This is 
illustrated by osteopenia in mice with loss of function of the WNT co-receptor LRP5 or in 
mice exposed to elevated levels of the WNT inhibitor DKK1 (34). It must be noted that the 
level of expression of FRZB/sFRP3 in BMPC, though significantly elevated as compared to 
memory B cells and plasmablasts, is way below the level found in most MM samples (Figure 
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5). We have also observed that the chemokine MIP1alpha/MIP1A/CCL3 is induced during PC 
differentiation. This chemokine has been shown to be an osteoclastogenic factor (35). 
Microarray analysis of human PCs has revealed the preferential expression of B cell 
activating factor BCMA/TNFRSF17 on plasmablasts and mature PCs, revealing BCMA as a 
typical PC gene (Figure 5) (2, 16, 36). Transmembrane activator and calcium signal–
modulating cyclophilin ligand interactor (TACI)/TNFRSF13B is a closely related receptor that 
is also induced during PC differentiation (Figure 5). BCMA and TACI are members of the 
TNF receptor family with two ligands of the TNF family: A Proliferation-Inducing Ligand 
APRIL/TNFSF13 and B Cell Activating Factor BAFF/TNFSF13B. In addition, BAFF also 
ligates a third TNFRSF receptor, BAFF-Receptor BAFFR/TNFRSF13C. Studies with knock-
out and transgenic mice has shown that the BAFF/BAFFR axis has an essential role in the 
maturation and the survival of peripheral B cells, BCMA has a critical role for the survival of 
long-lived bone marrow PCs, whereas TACI participates in T cell−independent immune 
responses and isotype switching (37-40). The expression of APRIL in B cells and mature 
plasma cells (Figure 5) and the very strong expression of APRIL in osteoclasts, monocytes 
and the myeloid lineage (41) suggests that plasma cells are exposed to the cognate ligand of 
BCMA in their bone marrow niche. Interestingly, it was recently established that APRIL can 
bind syndecan-1, a proteoglycan that is a hallmark of PC differentiation (42). These findings 
strongly suggest that BCMA plays an important role in human PC survival as it does in mice, 
with consequences for therapeutic intervention in non-malignant or malignant plasma cell 
disorders like MM (discussed below).  
 PCs are the main hematopoietic cells that express the heparan sulfate proteoglycan 
syndecan-1/SDC1/CD138 (43). In addition to PCs, preB lymphocytes may also express 
CD138, but not mature B lymphocytes, nor the other hematopoietic cell populations (44). 
This unique feature has opened the way to identify and to purify normal and malignant PCs 
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from bone marrow or blood to homogeneity using magnetic bead selection (22, 45). SDC1 is 
a typical late PC gene, whose expression begins after the plasmablast stage (Figure 2). 
Interestingly, in addition to a role in cell adhesion by promoting homotypic cell aggregation, a 
crucial function for SDC1 is to be cofactor in many signalling pathways by binding heparin 
binding growth factors, thereby increasing the availability of these molecules to the PCs (46). 
The list of secreted soluble ligands sequestered by SDC1 is rising and includes Hepatocyte 
Growth Factor (HGF), Osteoprotegerin (OPG), Fibroblast Growth Factors (FGFs), 
chemokines, some members of the TGF superfamily, and very recently APRIL (42, 46, 47).  
Four years ago, we found a major expression of the tyrosine kinase TYRO3 in some HMCL. 
TYRO3 is part of a family of tyrosine kinase transmembrane receptors that also encompasses 
the closely related receptors MERTK and AXL. This family of tyrosine kinase is involved in 
several physiological processes, including amplification of platelet aggregation, control of 
inappropriate immune responses, spermatogenesis and regulation of osteoclastic bone 
resorption (48-51). In addition, these receptors are overexpressed by many tumors and can 
transform cultured cells in vitro (52, 53). We gathered a remarkable body of expression data 
regarding this signalling pathway in plasma cells. Although TYRO3 is not expressed in normal 
PCs or primary malignant PCs, MERTK and AXL are expressed at the terminal stage of PC 
differentiation as shown in Figure 5. Moreover, the expression of the ligand of these three 
receptors, Growth Arrest-Specific 6 (GAS6), is turned on in PCs. These observations give 
compelling evidence that this signalling pathway is involved in the biology of ASC. TYRO3 
activation by GAS6 induces osteoclastic bone resorption in mice (49), thus this signaling axis 
could play a role in the physiological interaction of PCs with bone. However, this hypothesis 
does not clarify the meaning of the upregulation of TYRO3 in some HMCL. Therefore, careful 
functional analysis will be mandatory to determine the exact role of the expression of these 
receptors and their ligand by normal and malignant PC. 
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 Memory B cells and BMPC are cells with a prolonged survival in vivo, in contrast to 
plasmablasts that are cell highly prone to apoptosis and die if they are deprived of the access 
to a survival niche. Expression of several anti-apoptotic members of the BCL2 family varies 
accordingly. Memory B cells express high levels of BCL2A1/A1 and BCL2 (Figure 6). BMPC 
express markedly BCL2 and MCL1. In contrast, plasmablasts express no or little of these anti-
apoptotic molecules. These characteristics may explain why plasmablasts are doomed to die 
by apoptosis as observed for plasmablasts after 8 days of in vitro differentiation of peripheral 
blood B lymphocytes or for plasmablasts from reactive plasmacytosis (16, 32). It is likely that 
in the case plasmablasts reach the appropriate bone marrow niche, they receive signals that 
result in the expression of antiapoptotic proteins such as BCL2 and MCL1. Another 
observation in line with the pre-apoptotic state of plasmablasts is the expression of caspase 6 
(CASP6) by these cells (2). 
 
2.6. Cell cycle 
Peripheral blood memory B cells and BMPC are cells that are not cycling, in contrast to 
plasmablasts that can have more than 30% of the cells in the S-phase (16). It is therefore not 
surprising to observe in plasmablasts the very strong expression of more than one hundred 
genes involved in the cell cycle progression (unpublished results). Some typical examples are 
depicted in Figure 6, such as the Budding Uninhibited by Benzimidazoles 1 homolog (BUB1) 
gene or the minichromosome gene MCM2. Of note, cyclin D2 (CCND2) is the cyclin D that is 
highly expressed in proliferating non-malignant plasmablasts, whereas CCND1 is not 
expressed and CCND3 expression level does not vary markedly during PC differentiation. 
 
2.7. Immunoglobulin secretion and the unfolded-protein response 
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 During PC differentiation, as a consequence of the induction of PRDM1 and the 
repression of PAX5, Ig production is switched to a secreted form and is massively 
upregulated. This results in the overflow of the polypeptide processing and folding machinery 
in the endoplasmic reticulum (ER) and generates a stress signal to the cell. This warning is the 
primary signal for a highly coordinated response called the unfolded protein response (UPR) 
resulting in the production of ER chaperones and enzymes assisting in the protein folding. 
Thus, the UPR adapts the capacity of the secretory system to the load of the protein synthesis 
by transcriptional up-regulation of genes that function in all aspects of ER protein processing 
and metabolism. The link between plasma cell differentiation and UPR was demonstrated by 
the finding that the X-box binding-protein 1 (XBP1) basic-region leucine zipper transcription 
factor, which was found as the functional equivalent to the yeast Hac1p UPR activating 
transcription factor (54), was also shown to be required for PC differentiation (55). 
Microarray technology has significantly contributed to the understanding of the complex but 
coordinated UPR in mammalian cells. The molecular profiling induced by the expression of 
XBP1 was studied in mice in wild type and XBP1-/- B-cells and embryonic fibroblasts, and in 
the human RAJI lymphoma cell line. Major proteins involved in this coordinated UPR are 
schemed in Figure 7A. 
 UPR is turned on in mammalian cells by the activation of three bZIP transcription 
factors: ATF6, ATF4 and XBP1. Following ER stress, the membrane-tethered precursor of 
ATF6 is relieved from its interaction with the Heat Shock 70kDa Protein 5/HSPA5/BIP, is 
cleaved and the N-terminal DNA-binding domain is translocated to the nucleus where it 
activates the transcription of XBP1 (Figure 7A). In parallel, the transmembrane kinase and 
endonuclease Endoplasmic Reticulum to Nucleus Signalling 1 ERN1/IRE1 is also liberated 
from HSPA5, resulting in the unconventional splicing of XBP1 which thereby becomes fully 
functional. The transcriptional activity of ATF6 and XBP1 are the corner stone of the 
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expression of the UPR. In PCs, XBP1 expression is upregulated and spliced (56), and 
accordingly, many genes induced during PC differentiation are also found induced by the 
overexpression of XBP1 alone (57, 58). This common profile includes genes targeting 
proteins across the ER membrane (SRP54, RPN1, etc.), translocation of proteins across the 
ER membrane (SSR1, SSR3, SSR4, SEC61A1, etc.), folding of ER proteins (DNAJB9/ERdj4, 
HSPA5, DNAJC3, DNAJB11/HEDJ etc.), oxidative protein folding, i.e. formation of disulfide 
bonds (ERO1L), the degradation of misfolded protein (EDEM2, SEL1L, HERP/HERPUD1, 
etc.), protein glycosylation (SLC33A1, DDOST, FUT8, etc.), ER-Golgi trafficking (SEC23B, 
ARCN1, etc.). Interestingly, the third bZIP transcription factor, ATF4 does not seem to be 
active because two major ATF4 downstream targets, CHOP and GADD34, have expression 
level similar in BMPC and B memory cells. Activation of CHOP is part of an ER stress 
program that results in protein translation stop and apoptosis (59). Absence of significant 
activation of this pathway suggests that the physiological load of newly synthetized Ig is 
correctly handled by the UPR and that the stress response resulting in CHOP activation is not 
triggered during normal PC differentiation (57). Our current data shows the power of 
microarrays to investigate as a whole the expression of UPR genes in PC differentiation. 
Figure 7B shows 22 UPR genes that are upregulated in plasmablasts and PC compared to 
memory B cells. 
 
 
3. Input of microarray for the understanding of malignant plasma cell dyscrasias 
3.1. Short outline of malignant plasma cell dyscrasias and gene abnormalities 
3.1.1. Malignant plasma cell dyscrasias.  
MM is a B-cell neoplasia that affects about 15 000 new patients per year in Europe and about 
the same number in the United States. The median age at diagnosis is 67 years. MM is 
characterized by the accumulation of a clone of plasma cells in the bone marrow. In a 
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minority of patients with plasma cell leukemia (PCL), myeloma cells can grow and survive 
without the support of the bone marrow environment. The MM clone harbors somatic 
mutations of the immunoglobulin genes, which remain stable throughout the disease (60). 
This indicates that the “myeloma stem cell” originates from a cell that underwent antigen 
selection in the germinal centers, either a memory B cell or a plasma cell. High dose 
chemotherapy (HDT) increases the median overall survival of newly diagnosed patients to 
about 5-7 years in randomized clinical trials, though this is still a matter of discussion (61). 
The advent of new compounds such as thalidomide (62), its derivatives or bortezomib (63) 
has improved the treatment of patients in relapse from high dose chemotherapy and may also 
improve induction treatment before HDT (64). Compared with the general population, MM 
occurs more frequently in patients with MGUS, a pre-malignant condition, with an annual 
rate of transformation of MGUS into MM of about 1%. MGUS is frequent in the elderly, 
about 3% of the individuals over 70 years old (65).  
 
3.1.2. Chromosome abnormalities in MM.  
A major advance in the biology of MM has been the identification of gene abnormalities 
using conventional cytogenetics or fluorescence in situ hybridization (FISH). This field was 
recently reviewed by Fonseca et al. (66). Karyotypic instability is a hallmark of MM (67). By 
metaphase cytogenetics, chromosome abnormalities can be detected in about 30% of patients 
with newly diagnosed MM. Using FISH on CD138-selected cells or with immunostaining of 
intracytoplasmic immunoglobulin light chains to identify plasma cells, chromosome 
aberrations can be detected in virtually all patients at the time of first diagnosis. Based on the 
data of metaphase cytogenetics, two partially overlapping pathogenetic pathways have been 
proposed: non-hyperdiploid MM (comprising MM with hypodiploid, pseudodiploid and near-
tetraploid karyotypes), characterized by recurrent translocations involving the 
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immunoglobulin heavy chain gene (IgH) on chromosome 14q32.3 and with a high incidence 
of 13q loss, and hyperdiploid MM associated with multiple trisomies involving chromosomes 
3, 5, 7, 9, 11, 15, 19, and 21, but a lower incidence of IgH-translocations and 13q aberrations 
(68-70). About 50% of MM patients have hyperdiploid tumors. Recently, interphase FISH-
based assays distinguishing between hyperdiploid and non-hyperdiploid MM have been 
reported (71, 72). 
IgH-translocations are found in about 50% of patients with MGUS, 55-70% of patients with 
intramedullary MM, 80% of patients with primary PCL, and 90% of human myeloma cell 
lines (HMCL). Translocations affecting the immunoglobulin light chain genes (IgL) occur 
less frequently (< 20%) and mostly involve the IgL-λ locus. Chromosome partners have been 
identified in 40% of the cases and include chromosome 11q13, resulting in the deregulation of 
CCND1 (cyclin D1) and MYEOV in 16% of the patients, chromosome 4p16 resulting in the 
deregulation of FGFR3 and Wolf-Hirschhorn syndrome candidate 1 (WHSC1/MMSET) in 
15% of MM patients, chromosome 16q22-23 resulting in the deregulation of c-maf in 5% of 
MM patients and chromosome 6p21 resulting in the deregulation of CCND3 (cyclin D3) in 
4% of the patients. IgH-translocations define distinct entities of MM with clinical, 
morphologic, immunophenotypic, and therapeutic implications (66, 73, 74). Especially, the 
translocation t(4;14)(p16.3;q32.3) confers a bad prognosis even after high-dose therapy and 
autologous blood stem cell transplantation (75). IgH-translocations are also found in patients 
with MGUS indicating that they are early and possibly seminal events in the premalignant 
phase of the disease (66, 76). 
We have recently described a model for the clonal evolution of MM from initiation to first 
diagnosis based on results from interphase FISH (72). According to this model, translocation 
t(11;14), hyperdiploid, and non-hyperdiploid-karyotypes each define a distinct subgroup of 
the disease. Furthermore, patients with additional copies of chromosome 1q21 could represent 
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a poor prognosis group, indicated by significantly higher beta-2-microglobulin and lower 
hemoglobin levels. Deletions of 22q11, 8p12, 6q21 and 17p13 (TP53-locus) were found as 
subsequent or late events occurring in the course of the disease, but not defining subentities of 
MM.  
Deletion of chromosome 13q14 can be found by interphase-FISH in about 50% of patients 
with newly diagnosed MM. This aberration has repeatedly been described to be associated 
with poor prognosis. Its significance was confirmed for patients after autologous and after 
allogenic stem cell transplantation following dose-reduced induction therapy (77, 78). 
However, the translocation t(4;14) is in almost all cases associated with a deletion of 13q14, 
and overall survival seems to be significantly shorter for patients with both t(4;14) and 
deletion of 13q14 than for those with deletion of 13q14 alone (77).  
Deletions of chromosome 17p13 can been found in about 10-30% of patients with newly 
diagnosed MM (72, 79). This aberration has been reported to confer a grave prognosis for 
patients treated by conventional therapy. Furthermore, deletion of 17p13 was described to be 
an adverse prognostic factor following autologous stem cell transplantation(77, 80). 
 
RAS mutations are found in 35-50 % of newly diagnosed patients (66). RAS mutations are rare 
in patients with MGUS and increase in patients with progressive disease, suggesting that they 
contribute to disease progression.  
 
3.2. Gene expression profiling (GEP) in MM and patient classification 
3.2.1. GEP and patient classification 
Gene expression profiling of myeloma cells is thought to be utilizable to define distinct MM 
entities with different prognosis, and therefore stratify patients for adapted treatment. A first 
study comparing GEP of purified myeloma cells obtained from newly diagnosed patients with 
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MM or MGUS, of HMCLs and of purified bone marrow plasma cells from healthy 
individuals was published in 2002 by the group of John Shaughnessy (81). Using hierarchical 
clustering, myeloma cells could be subdivided into four groups. One group comprised the 
HMCL whereas another group integrated the normal bone plasma cells and MGUS samples. 
In the “HMCL-like” myeloma cell group, patients tended to have poor-risk profile including a 
higher serum β2m values and unfavorable cytogenetic abnormalities. Furthermore, the same 
group used microarrays to define molecular signatures of cells representing the stages of 
human B cell development, peripheral blood B cells, tonsillar B cells, tonsillar plasma cells 
and bone marrow plasma cells. They showed that myeloma cells from high-risk MM has a 
tonsillar B cell signature whereas myeloma cells from patients with low risk feature have 
bone marrow or tonsillar plasma cell signature (82). Using the expression profiles of 221 MM 
patients assessed with Affymetrix U95 microarrays, a different classification of patients into 
four groups with distinct cytogenetic characteristics (ploidy status, IgH-translocations, 
trisomy 11) and clinical parameters (β2m, IgA, albumin, creatinin, MRI lesions, and event 
free survival (EFS) and overall survival (OS)) was published (83). 100 genes were identified 
correlating with the EFS. Three genes had independent prognostic value: Ras-related nuclear 
protein (RAN), Zinc finger and homeodomain protein 2 (ZHX-2) and Chromosome 
condensation 1-like (CHC1L) (83). Patients with high RAN expression and low ZHX-2 and 
CHC1L expression had a relatively shorter EFS compared to patients with low RAN and high 
ZHX-2 and CHC1L expression. RAN encodes for a GTPase involved in several biological 
pathways: shuttle of protein and RNA through the nuclear pore complex, regulation of 
chromosome condensation, spindle formation, nuclear assembly and cell cycle progression. 
CHC1L is located on chromosome 13q14.3 and is a homolog of RCC1 which is a GTP 
exchange factor of RAN. ZHX-2 is a negative regulator of the NF-Y transcription factor, 
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which is involved in cell cycle control. Accordingly, a negative correlation of expressions of 
ZHX-2 and a panel of 30 proliferation genes was found.  
Currently, published GEP classifications vary considerably. A careful statistical validation on 
a sufficiently high number of patients, a longer follow up and testing in a prospective clinical 
trial is mandatory before a GEP classification might be used for clinical decisions. 
3.2.2. GEP and gene abnormalities 
The first reports combining GEP and cytogenetic data indicated that the 2 most prevalent 
translocations in MM are associated with high expression of the deregulated oncogenes (81). 
In patients with a t(4;14) translocation, a high expression of WHSC1/MMSET and FRGR3 is 
found in 100% and 80% of cases, respectively (84, 85). The t(11;14) translocation is 
associated with a high CCND1 expression. CCND1 is not expressed in normal lymphoid and 
hematopoietic cells, particularly normal plasmablastic and plasma cells (16) (Figure 6). Using 
expression profiles of 65 newly-diagnosed MM-patients obtained with Affymetrix U133 A+B 
microarrays, we confirmed that myeloma cells with t(4;14) and t(11;14) translocations can be 
easily visualized by a prominent expression of FGFR3, WHSC1/MMSET or CCND genes 
(see Figure 8). CCND1 expression is also found in myeloma cells without t(11;14) 
translocation (28) (Figure 8), either in the context of a light chain translocation, or correlated 
with a gain of the chromosomal region 11q13. Using microarrays, Bergsagel et al. point out 
that a high expression of one of the three cyclin D genes – CCND1, CCND2 or CCND3 – is a 
general feature of MM and proposes a classification of patients with MM within 8 groups 
(86). 
Combining FISH and GEP, we identified a 6-gene predictor for four groups of patients: group 
1.1 with intermediate CCND1 expression and gain of 11q13 without a translocation involving 
11q13, group 1.2 with high CCND1 expression and a translocation involving 11q13, mostly 
t(11;14)(q13;q32.3), group 2.1 with CCND2 expression without elevated FGFR3 expression, 
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and group 2.2 with CCCND2 expression, t(4;14) translocation and FGFR3 expression (87). 
This 6-gene predictor correctly classifies all patients in a training group of 65 patients, and 
about 90% of patients of an independent validation group comprising additional 65 patients 
We also found that the patients predicted to be in group 2.2 had the shortest event-free 
survival, in agreement with the known bad prognosis of t(4;14) (66). GEP can give some 
insight into the role of del13q analyzed by FISH or conventional cytogenetic (88) and 
indicates an upregulation of the ribosomal machinery in hyperdiploid clones with a low 
incidence of del13q (89). Presently, no data are published regarding the ability of microarrays 
to predict for del17 (P53 locus) that is associated with a poor clinical outcome after HDT 
(77). Thus, the combination of gene expression profiling and molecular cytogenetics like 
iFISH or aCGH is a promising approach and might facilitate the interpretation of expression 
data in the future. 
 
3.3. GEP and the tumor microenvironment 
3.3.1. Short outline of MM clone and tumor environment 
Although MM is characterized by a small growth fraction, the rate of proliferation is one of 
the best prognostic factors (90). In a majority of patients, the survival of myeloma cells is 
strongly dependent on interaction with the bone marrow environment (91), including 
endothelial cells, osteoblasts, osteoclasts, monocytes, and polymorphonuclear leukocytes. 
Myeloma cells, in turn, influence the bone marrow environment, e.g. by producing VEGF that 
stimulates neoangiogenesis (92). Angiogenesis is a marker of disease activity (93). Interaction 
between myeloma cells and bone marrow stromal cells has been widely documented. In 
particular, myeloma cells can trigger IL-6 production in bone marrow stromal cells through an 
NF- B-dependent pathway (94, 95). The increased osteoclast activity in MM is probably the 
result of a direct contact of these cells with myeloma cells (96). The crosstalk between 
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myeloma cells and the bone marrow environment involves chemokines and chemokine 
receptors, mainly CCR1 (97), CCR2 (98), MIP-1α (35) and MIP-1β (99), adhesion molecules 
(100), metalloproteinases (101) and production of growth factors (102). We and others 
identified IL-6 as a major myeloma cells growth factor in 1989 (103, 104), mainly produced 
by the microenvironment, in particular monocytes and stromal cells (105). IGF-1, hepatocyte 
growth factor, IL-10, IL-21 and more recently the epidermal growth factor family (EGF) and 
the BAFF/APRIL B cell growth factors were identified as myeloma cells growth factors (106-
108). 
3.3.2. Input of microarrays to identify novel myeloma cells growth factors 
DNA arrays have proven to be very useful for identifying novel myeloma cells growth 
factors. In our first transcriptome study of MM, we compared the GEP of HMCL and EBV 
transformed cell lines using nylon macroarrays dedicated to the analysis of 268 genes coding 
for growth factors or their receptors, and we identified several genes whose gene products 
were demonstrated to be important in myeloma cells biology: the heparin binding epidermal 
growth factor like growth factor (HB-EGF), the WNT pathway decoyed receptor 
(FRZB/sFRP3), the TYRO3 receptor for GAS6 factor, the IL-6 receptor, the IGF-1 receptor, 
the hepatocyte growth factor activator (HGFAC) (28). The use of microarrays measuring the 
expression of more than 30 000 genes has confirmed and extended these early findings. 
EGF family in MM. 
HB-EGF is expressed and used by some HMCLs as an autocrine growth factor, acting in 
synergy with IL-6 (28, 109). Using microarrays, we were able to screen the expression of the 
EGF family and their receptors and provide a general picture of the involvement of this 
signalling pathway in MM. The EGF family comprises 10 members and at least 4 of them can 
bind heparan sulfate chains: HB-EGF, amphiregulin, neuregulin-1, neuregulin-2 (110). This 
family binds to and induces the homo- or heterodimerization of three receptors: the 
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EGF receptor ErbB1, ErbB3, and ErbB4. ErbB2 is a fourth member unable to bind EGF 
ligands. ErbB2 is a preferred heterodimerization partner for all other ErbB members and 
increases ErbB receptor signaling (111).  
First, expression of EGF receptor family is a feature of plasma cell differentiation. Normal 
plasma cells express the ErbB1 and ErbB2 receptors unlike normal memory B cells or normal 
plasmablastic cells (112). Malignant plasma cells also expressed ErbB1, ErbB2 and in 
addition ErbB3 and ErbB4. Second, we found that HB-EGF is not expressed by primary 
myeloma cells but by the bone marrow environment, mainly by monocytes, 
polymorphonuclear leukocytes (107). More generally, only the EGF family members that are 
able to bind heparan sulfate chains (HB-EGF, amphiregulin, neuregulin-1, neuregulin-2) are 
able to trigger myeloma cells growth. This property is linked to the ability of these EGF 
members to bind at a high density to the surface of myeloma cells, through syndecan-1 (113) 
(Figure 9). Syndecan-1 is a heparan sulfate proteoglycan induced in plasma cell 
differentiation together with some EGF receptor members. As illustrated in Figure 9, one of 
the roles of syndecan-1 is to be a coreceptor for heparan sulfate binding EGF members 
favoring activation of specific ErbB receptor. Of interest, some myeloma cells acquire the 
capacity to produce HB-EGF initially produced by the microenvironment, which may confer 
an advantage for growing independently of the tumor environment. In parallel to these 
expression data, it was shown that the activation of ErbB receptor acts in synergy with 
activation of gp130 IL-6 transducer in some myeloma cell lines (109) and in epithelial cells 
(114, 115). In particular, Jelinek and collaborators demonstrated that ErbB3 activation can 
trigger phosphorylation of interferon receptor on myeloma cells (116). We found that a pan 
erbB kinase inhibitor can induce apoptosis of primary myeloma cells cultures for several days 
together with their bone marrow environment, further emphasizing the relevance of EGF 
family members to trigger primary plasma cell survival (107). These findings are of interest 
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since clinical grade inhibitors of the EGF receptor family are now under investigation in 
epithelial cancers (117).  
BAFF/APRIL growth factors 
Another example for the usefulness of microarrays in investigating the mechanisms of the 
growth of myeloma cells is provided by studies on BAFF and APRIL. These growth factors 
are essential for nonmalignant B lymphocyte and plasma cell development (see above). In an 
initial comparison of expression profiles of normal plasmablasts, bone marrow plasma cells, 
and B cells, we found that TACI and BCMA genes were overexpressed by plasma cells (16). 
We and others further demonstrated that BAFF and APRIL can support the growth of 
myeloma cells and that conversely an inhibitor of BAFF and APRIL can induce apoptosis of 
primary myeloma cells (108, 118). BAFF and APRIL genes are mainly expressed by the 
tumor environment, in particular monocytes and polynuclear cells (41). Of interest, we found 
a high production of APRIL in osteoclasts whereas bone marrow stromal cells did neither 
express BAFF nor APRIL (41). We also found that the gene coding for the APRIL receptor, 
TACI, had a clear-cut expression pattern in HMCL, being either “absent” or “present” (using 
the Affymetrix “call”). Respective data were confirmed by RT-PCR. Regarding primary 
myeloma cells, patients with myeloma cells highly expressing TACI (TACI++ myeloma cells) 
have a gene signature linked with microenvironment dependence in agreement with the 
production of these factors mainly by the tumor environment. Conversely, patients with 
myeloma cells weakly expressing TACI (TACI-/+ myeloma cells) have a plasmablastic gene 
signature. This was not found for other BAFF or APRIL receptors, BCMA or BAFF-R. Recent 
data on APRIL might help to understand the underlying mechanism. APRIL, unlike BAFF, is 
able to strongly bind to syndecan-1 (42). Of these two, only APRIL can bind at a high density 
to the surface of myeloma cells. This binding was abrogated by pretreatment of APRIL with 
heparin or of myeloma cells with heparitinase (unpublished observation). As BAFF does not 
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bind TACI, the property of APRIL to be concentrated at a high density on the myeloma cells 
membrane by syndecan-1 likely favors the emergence of myeloma cells that express the 
APRIL receptor TACI. This may explain the relevance of the microarray signature linked to 
the expression of TACI. Of note, we also found that some autonomous growing cell lines use 
APRIL as autocrine growth factor, in particular RPMI8226 (108). Thus, an interesting analogy 
exists between the results for APRIL/TACI and those for the EGF family. Both are important 
myeloma cells growth factors, in part due to the ability of syndecan-1 to concentrate them at a 
high density at the myeloma cells membrane. They are mainly produced by the bone marrow 
environment, but in some patients, myeloma cells can acquire the ability to express them and 
to become progressively independent of the tumor environment. 
 
3.3.3. GEP and the interaction of myeloma cells with bone cells 
DNA microarrays can also be used to gain insight in the interaction of myeloma cells with 
osteoblasts, osteoclasts and bone marrow stromal cells. Comparing the expression profile of 
myeloma cells from patients with or without osteolytic bone lesions, DKK1 was found to be 
overexpressed in the first group (119). DKK1 is an inhibitor of the WNT pathway and 
recombinant DKK1 is able to block the differentiation of mesenchymal stem cells into 
osteoblasts. Of note, some WNT family members are also myeloma cells growth factors (120) 
and a high expression of WNT5A is often found in patients with MM and is a growth factor 
for myeloma cells (120, 121). Thus, an overexpression of DKK1 in myeloma cells could 
possibly block the activation of the WNT pathway in myeloma cells and therefore the growth 
of myeloma cells. DKK1- myeloma cells have a plasmablastic phenotype (119). Using 
ATLAS macroarrays, HMCLs were found to overexpress the FRZB/sFRP3 gene (28). 
FRZB/FRP3 is a decoyed receptor for members of the WNT family blocking the activation of 
WNT receptors, and blocking also the differentiation of MSC into osteoblasts. As FRZB/FRP3 
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mRNA and protein are highly expressed by myeloma cells, FRZB/FRP3 might block bone 
formation in MM. The EGF members could also be involved in a blockade of bone formation 
in MM. Indeed, amphiregulin and HB-EGF produced by myeloma cells and/or the tumor 
environment are able to block the differentiation of MSC into osteoblasts (122, 123). We also 
reported a high expression of genes which may contribute to the interactions of myeloma cells 
with bone cells: GAS6, legumain and cystatin C (16, 121). HMCLs expressed TYRO3 and 
malignant and normal plasma cells expressed the two related receptors, AXL and MERTK (see 
Figure 5). TYRO3 is a receptor with kinase activity, which is expressed in mature osteoclasts 
in the bone marrow. The ligand of these receptors is GAS6 which is produced by normal and 
malignant PCs (Figure 5) (16).  
 
4. Conclusion 
Microarrays are a very powerful technology and give a precise overview of the known 
mechanisms involved in normal B-lymphocyte and plasma cell development and their 
physiological interaction with other cell populations, especially the bone marrow 
environment. The challenge will be to integrate to our knowledge of plasma cell biology the 
numerous genes that microarrays detect as induced or repressed during PC differentiation and 
that were never before described in this differentiation pathway. Similarly, microarrays will 
help to investigate the biology of plasma cell dyscrasias, the complex interactions between 
myeloma cells and the bone marrow environment and the major mechanisms of 
myelomagenesis underlying the overlapping distribution of a plethora of cytogenetic 
aberrations. Furthermore, it is likely that using advanced biostatistic approaches, a risk 
classification based on the expression profiling of the myeloma clone will provide a guide for 
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Legends to figures 
Figure 1 
The plasma cell transcription factor network. (A) Green boxes indicate transcription factors 
that are repressed during plasma cell differentiation and orange boxes transcription factors 
that are induced upon plasma cell differentiation. A solid line indicates a direct interaction of 
the transcription factor with the promoter of a target gene. Major events are the induction of 
PRDM1/BLIMP1 secondary to the inhibition of BCL6 activity, the repression of PAX5 
expression by PRDM1, that in turn drives the upregulation of XBP1. XBP1 is mandatory for 
plasma cell differentiation and for the unfolded protein response. See text of gene 
abbreviation. (B) Histograms show the expression level of 10 transcription factors regulating 
B-lymphocyte and plasma cell differentiation. Gene expression is measured by pan genomic 
HG-U133AB Affymetrix oligonucleotides microarrays and the signal intensity for each gene 
is shown on the Y axis as arbitrary units determined by the GCOS 1.2 software (Affymetrix). 
Each histogram features the same 21 samples: 7 peripheral blood CD27+ memory B-
lymphocytes samples (green boxes), 7 CD20- CD38+ plasmablasts samples obtained by in 
vitro differentiation of memory B-lymphocytes (orange boxes), and 7 CD138+ bone marrow 
plasma cells samples (red boxes). If the gene is not detected, i.e. the gene has an “absent” 
detection call in the GCOS 1.2 software, the box is left white. Histograms were generated 
with our “Amazonia!” web site (http://amazonia.montp.inserm.fr/). Genes on the left are 
preferentially expressed in B memory samples whereas gene on the right are preferentially 
expressed in plasma cell samples. The level of significance of the expression level variation 
between the three sample classes was assessed using a non parametric Kruskal-Wallis test. NS 
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The plasma cell phenotype. Histograms show the expression level of 11 genes coding for cell 
surface proteins characterizing B-lymphocytes or plasma cells. See legend in Fig 1B. 
 
Figure 3 
Chemokine receptors. (A) Histograms show the expression of 5 chemokines receptors 
characterizing B-lymphocytes or plasma cells. See legend in Fig. 1B. (B) Schematic 
representation of the expression of CCR7, CXCR5, CXCR4, CCR1 and CCR2 on memory B 
cells, plasmablasts and bone marrow plasma cells (BMPC). 
 
Figure 4 
Selectins and adhesion molecules. Histograms show the expression of 9 genes coding for 
adhesion molecules characterizing B-lymphocytes or plasma cells. See legend in Fig. 1B. 
 
Figure 5 
Growth factors and growth factor receptors. Histograms show the expression of 8 genes 
coding for receptors or receptor ligands characterizing B-lymphocytes or plasma cells. See 
legend in Fig. 1B. (*) Expression of FRZB in the same 21 normal B lymphocytes and plasma 
cells samples used in all histograms, plus CD138+ purified plasma cells from 19 patients with 
multiple myeloma (purple boxes). Note that the scale of the Y axis is different than in the 
histogram showing the expression of FRZB in nonmalignant B lymphocytes and PCs. Some 
MM samples display a striking overexpression of FRZB compared to BMPC samples. 
 
Figure 6 
Apoptosis and cell cycle. Histograms show the expression of 9 genes involved in cell cycle 
progression or apoptosis in B-lymphocytes or plasma cells. Note that cyclin D1 (CCND1) is 
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not expressed in normal B-lymphocytes or plasma cells (boxes are white), that CCND2 is 
highly overexpressed in plasmablasts, whereas CCND3 is expressed in all three cell 
categories with modest expression disparity across samples categories. See legend in Fig. 1B. 
ND : P-value not assessed because this gene was not detected in any sample. 
 
Figure 7  
Unfolded protein response (UPR). (A) A schematic view of the UPR in plasma cells in 
response to the expression of XBP1 and immunoglobulins (Ig). With the increasing load of 
proteins in the endoplasmic reticulum (ER) due to the massive translation of Ig, the heat 
shock protein HSPA5/BIP is displaced from proteins such as ATF6, ERN1/IRE1 and 
EIF2AK3/PERK to newly synthetized Ig. The dissociation of HSPA5 from ATF6 induces the 
cleavage of ATF6. The nuclear form of ATF6 (ATF6(N)) induces the expression of target 
genes, including XBP1, by binding a ER stress response element (ERSE) in their promoter. 
The release of ERN1 from HSPA5 induces the homodimerization of this kinase, self-
phosphorylation and activation of its endoribonuclease activity. ERN1 activity results in an 
unconventional splicing of XBP1: XBP1(S). XBP1(S) is in turn able to activate the UPR by 
binding to the UPR response element (UPRE) in target genes. UPR genes includes genes 
involved in ER targeting, ER membrane translocation, protein folding, oxidative protein 
folding, misfolded protein degradation, protein glycosylation and ER-golgi trafficking. The 
release of EIF2AK3 induces the activation of this kinase and the subsequent phosphorylation 
of EIF2A. Phosphorylation of EIF2A turns off protein translation and activates ATF4, which 
induces the expression of CHOP and GADD34. Overexpression of CHOP is associated 
induction of apoptosis. Orange boxes stand for genes that are found upregulated in plasma 
cells and purple boxes stand for genes whose expression does not change during normal 
plasma cell differentiation. 
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(B) Histograms show the expression of 22 genes coding for proteins involved in the UPR. See 
legend in Fig. 1B. 
 
Figure 8 
Expression of Fibroblast growth factor receptor 3 (FGFR3), Wolf-Hirschhorn syndrome 
candidate 1 (WHSC1/MMSET) and cyclin D1 (CCND1) in non malignant memory B 
lymphocytes (B) plasmablasts (PB) and bone marrow plasma cells (BMPC), in monoclonal 
gammapathy of unknown significance (MGUS), multiple myeloma (MM) and human 
myeloma cell lines (HMCL). Expression was measured by pan-genomic Affymetrix U133AB 
microarrays and visualized using our “Amazonia!” web site 
(http://amazonia.montp.inserm.fr/). See legend in Fig. 1B. The presence of t(4; 14) and 
t(11;14) translocations was evidenced by FISH analysis and is indicated on the histograms by 
colored circles : white circle : no t(4;14); red circle : t(4;14); grey circle : no t(11;14); green 
circle : t(11;14) in all myeloma cells; pale green circle : t(11;14) in a myeloma cell subclone 
only; no circle : no FISH analysis. 
 
Figure 9 
Syndecan-1 concentrates on the myeloma cell membrane large levels of heparan-sulfate 
binding epidermal growth factor (HB-EGF) family members that are produced by the tumor 
environment or by myeloma cells. This concentration step is critical for the activity of these 
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